Amgen Reports Positive Phase 3 Results for Sjögren's Disease Treatment

Key Facts

In a move reflecting the ongoing advancement in the biotech sector to address rare autoimmune conditions, Amgen has announced positive topline results from its Phase 3 OASIZ 301 study. According to reports, the drug dazodalibep met its primary endpoint, demonstrating statistically significant and clinically meaningful improvement in systemic disease activity for adults with moderate-to-severe Sjögren's disease. This study aims to provide a viable treatment path for patients suffering from debilitating symptoms who currently face very limited therapeutic options.

These clinical results strengthen Amgen's position as a key constituent of the Nasdaq-100 and Dow Jones Industrial Average, as successful Phase 3 trials typically signal potential regulatory submissions and future revenue growth. Per market data, AMGN stock stood at $393.16 (close September 21, 2026), having traded between a day high of $394.5 and a day low of $381.9, highlighting investor sensitivity to clinical milestone developments.

Looking ahead, market participants are monitoring the OASIZ 303 study, which is expected to conclude in Q4 2026. With AMGN priced at $393.16 (close September 21, 2026), broader macroeconomic factors also remain in focus following the Federal Reserve's decision on September 16, 2026, to raise interest rates to 4%, a move that influences financing dynamics across the large-cap healthcare sector.